默沙东砍掉IL-2与康方单抗项目，21亿美元投入或打水漂

Ofweek光电信息网2025-07-31

7月29日，默沙东于在发布的第二季度项目进展报告中披露，公司决定终止多个重磅研发项目，以配合其正在推进的大规模成本削减计划，并重新配置资源以支持未来增长重点。其中引人关注的，其中最受关注的两项包括：通过19亿美元从Pandion Therapeutics 手中收购获得的自身免疫疾病资产—IL-2突变蛋白MK-6194（原PT001），以及与康方生物合作开发的CTLA-4抗体MK-1308在非小细胞...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555003744?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-31 13:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555003744","market":"us","top_or_hot":-1,"title":"默沙东砍掉IL-2与康方单抗项目，21亿美元投入或打水漂","media":"Ofweek光电信息网","content":"<div>\n<p>7月29日，默沙东于在发布的第二季度项目进展报告中披露，公司决定终止多个重磅研发项目，以配合其正在推进的大规模成本削减计划，并重新配置资源以支持未来增长重点。其中引人关注的，其中最受关注的两项包括：通过19亿美元从Pandion Therapeutics 手中收购获得的自身免疫疾病资产—IL-2突变蛋白MK-6194（原PT001），以及与康方生物合作开发的CTLA-4抗体MK-1308在非小细胞...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113411394c56995&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东砍掉IL-2与康方单抗项目，21亿美元投入或打水漂</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东砍掉IL-2与康方单抗项目，21亿美元投入或打水漂\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 13:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113411394c56995&s=b><strong>Ofweek光电信息网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月29日，默沙东于在发布的第二季度项目进展报告中披露，公司决定终止多个重磅研发项目，以配合其正在推进的大规模成本削减计划，并重新配置资源以支持未来增长重点。其中引人关注的，其中最受关注的两项包括：通过19亿美元从Pandion Therapeutics 手中收购获得的自身免疫疾病资产—IL-2突变蛋白MK-6194（原PT001），以及与康方生物合作开发的CTLA-4抗体MK-1308在非小细胞...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113411394c56995&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1983299246.USD","symbol_name":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113411394c56995&s=b","article_id":"2555003744","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113411394c56995&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555003744","pubTimestamp":1753939980,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月29日，默沙东于在发布的第二季度项目进展报告中披露，公司决定终止多个重磅研发项目，以配合其正在推进的大规模成本削减计划，并重新配置资源以支持未来增长重点。默沙东更新后管线MK-6194来自默沙东2021年对Pandion Therapeutics的收购，当时默沙东以高达19亿美元的价格将这家专注于调节性T细胞治疗的生物技术公司收入麾下，MK-6194即为其最核心资产。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","09926":"康方生物","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MRK":"默沙东","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4559":"巴菲特持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A"},"translate_title":"Merck cuts off IL-2 and Akesomab projects, investment of US $2.1 billion may be wasted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"09926":0.9},"content_text":"7月29日，默沙东于在发布的第二季度项目进展报告中披露，公司决定终止多个重磅研发项目，以配合其正在推进的大规模成本削减计划，并重新配置资源以支持未来增长重点。其中引人关注的，其中最受关注的两项包括：通过19亿美元从Pandion Therapeutics 手中收购获得的自身免疫疾病资产—IL-2突变蛋白MK-6194（原PT001），以及与康方生物合作开发的CTLA-4抗体MK-1308在非小细胞肺癌（NSCLC）中的研发项目。默沙东更新后管线MK-6194来自默沙东2021年对Pandion Therapeutics的收购，当时默沙东以高达19亿美元的价格将这家专注于调节性T细胞治疗的生物技术公司收入麾下，MK-6194即为其最核心资产。该药物旨在通过选择性激活调节性T细胞，治疗包括系统性红斑狼疮、白癜风和溃疡性结肠炎等多种自身免疫性疾病。MK-6194 正在狼疮和白癜风的两项 2 期试验中进行研究。此前的1a期试验结果曾显示其具有良好的安全性与耐受性，且未见竞争对手产品中出现的NK细胞扩增问题。然而，根据默沙东对狼疮与白癜风适应症中期临床试验的主要结果，以及其他早期研究的评估，MK-6194并未展现出临床获益，公司因此决定将其从整体管线中剔除。默克发言人表示：“该决定是基于对 MK-6194-007 试验的主要结果和其他适应症的探索性 1b 期结果的全面审查，这些结果表明 MK-6194 没有带来临床益处。\"与此同时，默沙东也终止了与中国康方生物合作开发的MK-1308在非小细胞肺癌（NSCLC）中的研发。该项目最初来自双方2015年达成的合作协议，默沙东曾为此支付2亿美元。MK-1308是一款CTLA-4单克隆抗体，也叫quavonlimab，由默沙东与中国康方生物联合开发，曾计划与重磅免疫疗法Keytruda联用。终止的决定源于一项刚于今年6月完成的2期临床试验。试验共纳入245名NSCLC患者，主要评估缓解率，但结果未达到预期效果。值得一提的是，MK-1308并未完全“出局”，该抗体目前仍在肾细胞癌方向推进3期研究。此次研发项目的调整，是默沙东为落实其到2027年每年节省30亿美元开支计划的一部分。公司表示，节省下来的资金将“全部再投入”到重点新产品的上市与商业化中。从最新财报来看，默沙东正处于增长转型的关键阶段。其王牌产品Keytruda（可瑞达）本季度销售额首次突破80亿美元，同比增长9%，贡献了公司总营收的一半以上。相比之下，另一款重磅产品HPV疫苗Gardasil（佳达修）则受到冲击，季度销售额下滑55%至11亿美元，主要原因是中国市场需求骤减。默沙东目前已暂停对中国的疫苗供应，并表示将重新评估2026年的供应安排。在Keytruda即将面临专利悬崖、Gardasil需求波动的背景下，公司正加快资源重配。CEO Rob Davis 明确表示，未来将把重点投入快速成长的潜力管线。默沙东目前宣称拥有20多个具“重磅潜力”的研发项目。为此，公司正进行组织结构调整，通过优化行政、销售和研发人员编制，同时在关键业务板块增设岗位，以提升整体效率。尽管内部在“瘦身”，默沙东在资本市场上却仍在大手笔投资。7 月 9 日，公司宣布以100亿美元收购Verona Pharmaceuticals及其治疗慢性阻塞性肺病（COPD）的创新药Ohtuvayre，这也是今年全球第二大生物医药收购案。从第二季度整体业绩看，默沙东实现全球销售额158亿美元，同比下降2%。但如果不计中国市场的影响，整体营收仍实现了7%的增长。面对专利压力和市场变化，默沙东正在通过战略收缩与结构优化并举，稳固其未来增长基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555003744","isCrawlerRequest":true}